Vaxxinity Q3 EPS $(0.10) Beats $(0.12) Estimate
Portfolio Pulse from Benzinga Newsdesk
Vaxxinity (NASDAQ:VAXX) reported Q3 losses of $(0.10) per share, beating the analyst consensus estimate of $(0.12) by 16.67%. This represents a 33.33% increase over losses of $(0.15) per share from the same period last year.
November 08, 2023 | 1:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vaxxinity's Q3 earnings beat analyst estimates, showing a 33.33% improvement YoY.
Vaxxinity's Q3 earnings beat analyst estimates, which is generally seen as a positive sign by investors. The YoY improvement in losses also indicates that the company's financial health is improving, which could lead to a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100